# Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

Source: https://onco.cc/trials/nct07446855/  
OnCo record `nct07446855` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Saruparib in advanced solid tumours, run by AstraZeneca, now recruiting.

## Summary

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours is a phase 1/2 interventional study registered as NCT07446855 by AstraZeneca, with 180 participants planned, started 2026-03-17 and due to reach its primary completion in 2030-03-29. Interventions recorded: AZD4956 and Saruparib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07446855
- Phase: 1/2
- Setting: A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours
- Sponsor: AstraZeneca
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT07446855: https://clinicaltrials.gov/study/NCT07446855

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Saruparib](https://onco.cc/drugs/saruparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07446855.json